Brokerages forecast that Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) will announce earnings of ($0.06) per share for the current quarter, according to Zacks. Zero analysts have issued estimates for Diffusion Pharmaceuticals’ earnings, with estimates ranging from ($0.06) to ($0.05). Diffusion Pharmaceuticals posted earnings per share of ($0.63) in the same quarter last year, which would suggest a positive year over year growth rate of 90.5%. The company is expected to announce its next quarterly earnings report on Thursday, August 13th.
On average, analysts expect that Diffusion Pharmaceuticals will report full year earnings of ($0.25) per share for the current fiscal year, with EPS estimates ranging from ($0.27) to ($0.22). For the next year, analysts expect that the firm will report earnings of ($0.24) per share, with EPS estimates ranging from ($0.24) to ($0.23). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Diffusion Pharmaceuticals.
Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02.
A number of research firms recently issued reports on DFFN. ValuEngine raised shares of Diffusion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, March 18th. HC Wainwright restated a “buy” rating and set a $3.50 price objective on shares of Diffusion Pharmaceuticals in a research note on Thursday, March 19th.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Barclays PLC purchased a new stake in shares of Diffusion Pharmaceuticals during the fourth quarter worth $71,000. Acadian Asset Management LLC grew its position in Diffusion Pharmaceuticals by 1,360.0% in the 4th quarter. Acadian Asset Management LLC now owns 248,311 shares of the company’s stock worth $114,000 after purchasing an additional 231,303 shares during the period. Geode Capital Management LLC grew its position in Diffusion Pharmaceuticals by 2,396.7% in the 4th quarter. Geode Capital Management LLC now owns 251,163 shares of the company’s stock worth $115,000 after purchasing an additional 241,103 shares during the period. Finally, Renaissance Technologies LLC grew its position in Diffusion Pharmaceuticals by 797.7% in the 4th quarter. Renaissance Technologies LLC now owns 758,292 shares of the company’s stock worth $349,000 after purchasing an additional 673,820 shares during the period. 7.15% of the stock is owned by hedge funds and other institutional investors.
Diffusion Pharmaceuticals stock traded down $0.06 during trading on Monday, reaching $1.02. The stock had a trading volume of 79,811 shares, compared to its average volume of 5,802,844. Diffusion Pharmaceuticals has a 52-week low of $0.21 and a 52-week high of $3.35. The business has a 50 day moving average price of $0.89 and a 200 day moving average price of $0.53. The company has a quick ratio of 9.10, a current ratio of 9.10 and a debt-to-equity ratio of 0.01. The stock has a market cap of $48.93 million, a PE ratio of -0.58 and a beta of 1.37.
About Diffusion Pharmaceuticals
Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.
Featured Story: Is the Dow Jones Industrial Average (DJIA) still relevant?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.